Dr. Morrison, president of OmniSeq℠ Precision Medicine Technology, is featured as a “leading voice” in precision medicine. Buffalo, NY – June 29, 2015—The digital publication Future of Personal Health focuses on precision medicine in an article entitled Precision...
Company Expands Member Network to Advance the Clinical Utility of Genomic Medicine Buffalo, NY – August 03, 2015 – OmniSeq, LLC today announced the addition of the Wilmot Cancer Institute to the OmniSeqSM Genomic Network. Recently, OmniSeq officially spun out from...
By Alan Rosenhoch, Featuring Carl Morrison, MD, DVM Dr. Carl Morrison is founder, president and chief scientific officer of OmniSeq LLC – a recent Roswell Park Cancer Institute spinoff genomics firm. At Roswell Park, Dr. Morrison continues in his roles as Executive...
Buffalo has an emerging cluster of companies dedicated to cancer treatment that are showing significant signs of progress. Of course, the formation of oncology companies is nothing new in Buffalo, especially given institutional research strongholds like the University...
June 3-7 | Chicago, I Join us @ASCO 2022. LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers.
Sunday, June 5, 8-11:00 AM CDT
June 3-7 | Chicago, IL Join us at the @ASCO 2022. Comprehensive transcriptomic analysis of immune checkpoint markers in a pan-cancer cohort: Implications for response and resistance.
#376244-Developmental Therapeutics—Immunotherapy Sunday, June 5, 2022, 8:00 AM -11:00 AM CDT
June 3-7 | Chicago, IL Join us at the 2022 ASCO Annual Meeting.
Comprehensive genomic and immune profiling defines immunotherapy treatment in NSCLC patients with low PD-L1 IHC.
#2623 -Developmental Therapeutics—Immunotherapy
Sunday, June 5, 2022, 8:00 AM -11:00 AM CDT
Last year, the Buffalo-based cancer diagnostics firm @OmniSeq quietly was acquired by one of the world's largest life science companies, @Labcorp . Developing molecular diagnostic tests for cancer patients, OmniSeq is looking to scale its operations.